Meeting
2012 Genitourinary Cancers Symposium
Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).
Authors
Michael E. Rader
Union State Bank Cancer Center, Nyack Hospital, Nyack, NY
Michael E. Rader , Mark Danese , Ze Cong , Marc Halperin , Yi Qian , Carsten Dietrich Goessl , Karen Chung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00321620
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 59)
DOI
10.1200/jco.2012.30.5_suppl.59
Abstract #
59
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2014 Genitourinary Cancers Symposium
Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.
First Author: Matthew R. Smith
Poster
2011 ASCO Annual Meeting
Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain.
First Author: N. D. Shore
Poster
2013 Genitourinary Cancers Symposium
Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance).
First Author: Matthew Raymond Smith